Clearview Wealth Advisors’s DexCom DXCM Stock Holding History

Clearview Wealth Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16	Closed	-$1.46K	–	600
2022 Q1	$2K	Hold	16	–	–	﹤0.01%	519
2021 Q4	$2K	Buy	+16	New	+$2.3K	﹤0.01%	582

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearview Wealth Advisors's DXCM Position: Q2 2022 in Review

Clearview Wealth Advisors sold out of DexCom (DXCM) in Q2 2022, closing a stake of 16 shares — an estimated $1.46K sold.

Clearview Wealth Advisors first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Clearview Wealth Advisors reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Clearview Wealth Advisors sold 16 DexCom shares in Q2 2022, an estimated $1.46K.
Clearview Wealth Advisors first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
Clearview Wealth Advisors's DexCom position peaked at $2K in Q1 2022.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Clearview Wealth Advisors's 13F filing for Q2 2022, filed 5 Aug 2022.